Cronos Australia Ltd. (VIT) AI Stock Analysis

• Market Cap: AU$41.09M
• Dividend Yield: 3.08%
• Average Volume (3M): 228.84K
• Price to Earnings (P/E): 11.5
• Beta (1Y): 1.68
• Revenue Growth: 0.13%
• EPS Growth: -12.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 662,741,800
• 10 Day Avg. Volume: 238,134
• 30 Day Avg. Volume: 228,844
• PEG Ratio: -1.01
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 0.30
• P/FCF Ratio: 14.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: AU$0.07 ▲(11.67% Upside)

Cronos Australia Ltd.'s overall stock score is primarily influenced by its stable financial position and attractive valuation. However, the bearish technical indicators and challenges in revenue growth and cash generation weigh down the score. The absence of recent earnings call insights or notable corporate events means these factors do not impact the score.

Positive Factors

Strong Equity Base

A strong equity base indicates financial stability and resilience, providing a solid foundation for future growth and investment opportunities.

Product Diversification

Diversification across medicinal and recreational cannabis markets helps mitigate risks and capture a broader customer base, supporting long-term revenue stability.

Strategic Partnerships

Strategic partnerships expand market reach and enhance product innovation, strengthening competitive positioning and long-term growth potential.

Negative Factors

Revenue Growth Challenges

Sluggish revenue growth can hinder expansion and investment capabilities, potentially impacting long-term profitability and market competitiveness.

Cash Flow Concerns

Weak cash flow generation limits financial flexibility and the ability to fund operations, investments, and debt obligations, posing a risk to financial health.

Low Operational Efficiency

Low operational efficiency indicates potential cost management issues, which can affect profitability and the ability to compete effectively in the market.

Cronos Australia Ltd. Business Overview & Revenue Model

Company Description

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.

How the Company Makes Money

Cronos Australia Ltd. generates revenue primarily through the sale of cannabis products, including dried flower, oils, and other derivatives that are marketed to both medicinal and recreational users. The company has established a revenue model that includes direct sales to consumers via dispensaries, partnerships with licensed retailers, and potential export opportunities in international markets. Key revenue streams include wholesale distribution to pharmacies and health practitioners, as well as direct consumer sales through online platforms. Additionally, strategic partnerships with other companies in the cannabis ecosystem, such as cultivation technology firms and research institutions, enhance its product offerings and market reach, contributing to its overall earnings.

Cronos Australia Ltd. Financial Statement Overview

Summary

Cronos Australia Ltd. demonstrates a stable financial position with moderate profitability and a strong equity base. However, the company faces challenges in revenue growth and cash generation, which could impact its future financial performance. The balance sheet remains strong with manageable debt levels, but there is room for improvement in operational efficiency and cash flow management to enhance overall financial health.

Income Statement

Cronos Australia Ltd. has shown a mixed performance in its income statement. The company has experienced a slight decline in revenue growth recently, with a negative growth rate of -2.001% in the latest period. However, the gross profit margin remains relatively stable at 27.21%, indicating efficient cost management. The net profit margin is modest at 2.68%, reflecting some profitability but also highlighting potential challenges in converting revenue into net income. The EBIT and EBITDA margins are low, suggesting limited operational efficiency. Overall, the income statement reflects moderate profitability with room for improvement in revenue growth and operational efficiency.

Balance Sheet

The balance sheet of Cronos Australia Ltd. indicates a stable financial position with a debt-to-equity ratio of 0.25, suggesting a conservative approach to leverage. The return on equity is 6.90%, which is moderate and indicates some efficiency in generating returns for shareholders. The equity ratio stands at 63.85%, showing a strong equity base relative to total assets. Overall, the balance sheet reflects a stable financial structure with manageable debt levels and a solid equity position, although there is potential for enhancing shareholder returns.

Cash Flow

The cash flow statement reveals challenges in cash generation, with a significant decline in free cash flow growth at -2056.03%. The operating cash flow to net income ratio is low at 0.14, indicating limited cash conversion from net income. However, the free cash flow to net income ratio is relatively high at 0.97, suggesting that the company is able to convert a substantial portion of its net income into free cash flow. Overall, the cash flow position highlights potential liquidity concerns and the need for improved cash generation capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	124.04M	124.04M	123.87M	117.34M	66.99M	21.71M
Gross Profit	33.75M	33.75M	34.22M	25.96M	25.43M	3.19M
EBITDA	5.64M	5.64M	7.08M	21.08M	10.87M	2.12M
Net Income	3.32M	3.32M	3.51M	13.81M	6.05M	-4.05M
Balance Sheet
Total Assets	75.49M	75.49M	71.28M	46.90M	42.87M	12.69M
Cash, Cash Equivalents and Short-Term Investments	7.58M	7.58M	11.35M	18.85M	16.08M	9.47M
Total Debt	11.97M	11.97M	11.02M	1.71M	5.06M	718.02K
Total Liabilities	27.89M	27.89M	32.84M	11.99M	16.79M	3.47M
Stockholders Equity	48.20M	48.20M	38.78M	34.98M	26.10M	9.30M
Cash Flow
Free Cash Flow	2.58M	2.58M	6.21M	8.78M	13.13M	1.01M
Operating Cash Flow	2.67M	2.67M	7.00M	9.71M	13.50M	1.07M
Investing Cash Flow	-13.87M	-13.87M	-13.20M	-837.72K	2.00M	-160.69K
Financing Cash Flow	7.43M	7.43M	-1.30M	-6.10M	-1.50M	-262.03K

Cronos Australia Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of -13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$41.09M	11.48	7.64%	3.08%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXL	44 Neutral	$3.32M	-1.30	-26.84%	―	36.60%	85.28%
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
CAN	40 Underperform	AU$12.44M	―	-401.36%	―	-26.49%	61.72%
EPN	37 Underperform	$7.21M	―	―	―	-15.81%	-358.33%

Cronos Australia Ltd. Corporate Events

Vitura Health Establishes Industry Advisory Group to Boost Clinical Governance

Vitura Health Limited has announced the formation of an Industry Advisory Group to enhance its clinical governance and patient experiences. Chaired by Gerard Fogarty, the group will advise on medical practice management and emerging opportunities in the medicinal cannabis and specialty clinics industry, aiming to maintain industry-leading standards and improve patient outcomes.

Vitura Health Advances Digital Health Strategy at 2025 AGM

Vitura Health Limited held its 2025 Annual General Meeting, where three resolutions were passed, and one was withdrawn. The meeting highlighted the company’s strategic focus on expanding its digital health platform and integrating new opportunities such as psychedelic product distribution, reinforcing its position in the medicinal cannabis and telehealth markets.

Vitura Health Unveils Strategic Expansion at 2025 AGM

Vitura Health Limited announced the presentation for its 2025 Annual General Meeting, highlighting its ongoing efforts to expand its digital health platform and product distribution capabilities. The company’s strategic initiatives, including its joint venture for psychedelic products and the integration of telehealth services, position it as a significant player in the evolving healthcare market, potentially impacting stakeholders by broadening access to innovative health solutions.

Vitura Health Withdraws Resolution Ahead of AGM

Vitura Health Limited has announced the withdrawal of Resolution 3, concerning the ratification of shares issued to AFO Investments Pty Ltd, ahead of its 2025 Annual General Meeting. This decision may impact shareholder expectations and reflects the company’s strategic considerations in its ongoing operations and market positioning.

Vitura Health Announces CFO and Company Secretary Resignation

Vitura Health Limited announced the resignation of its Chief Financial Officer and Company Secretary, Tom Howitt, effective January 2026. Howitt, who has been with the company since its inception, played a crucial role in its ASX listing and strategic acquisitions. His departure marks a significant change in the company’s leadership, with recruitment for his replacement already underway.

Vitura Health Limited Announces Hybrid Annual General Meeting for 2025

Vitura Health Limited has announced its Annual General Meeting scheduled for November 26, 2025, which will be held in a hybrid format allowing both in-person and online participation. This meeting is crucial for shareholders as it provides an opportunity to vote on resolutions and engage with the company’s management, potentially impacting the company’s future strategies and stakeholder relations.

Vitura Health’s 2025 Annual Report: A Commitment to Future Healthcare and Reconciliation

Vitura Health Limited has released its 2025 Annual Report, emphasizing its commitment to building a future-focused healthcare network. The report highlights the company’s dedication to reconciliation with Aboriginal communities and acknowledges the Traditional Owners of the lands on which it operates. This announcement underscores Vitura Health’s strategic focus on strengthening relationships and fostering inclusivity, which is likely to enhance its industry positioning and stakeholder engagement.

Vitura Health Limited Updates Dividend Distribution Details

Vitura Health Limited has announced an update regarding its dividend distribution, providing details on the final Dividend Reinvestment Plan (DRP) allocation price and the number of shares to be issued. This update is part of the company’s ongoing financial management strategy, which may impact shareholder value and market perception as it relates to the financial period ending June 30, 2025.

Vitura Health Schedules 2025 Annual General Meeting

Vitura Health Limited has announced the scheduling of its 2025 Annual General Meeting for November 26, 2025. The meeting will cover various business items, and nominations for director elections are due by October 1, 2025. This announcement is part of Vitura’s ongoing efforts to maintain transparency and engage with its shareholders, reflecting its strategic focus on expanding its digital health operations and enhancing its market position in the medicinal cannabis and psychedelic sectors.

Cronos Australia Ltd. Announces Change in Substantial Holding

Cronos Australia Ltd. has announced a change in the substantial holding of Guy Rothwell Headley in Vitura Health Limited. The change, effective from September 5, 2025, results from an off-market transfer due to a financial agreement, reducing Headley’s voting power from 15.26% to 7.57%. This adjustment in holdings may impact the company’s governance and influence within Vitura Health Limited.